ASCO 2013 Prostate Cancer Intro

Article

Cancer Network and the journal ONCOLOGY present exclusive prostate cancer coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.

Cancer Network and the journal ONCOLOGY present exclusive prostate cancer coverage from the annual meeting of the American Society of Clinical Oncology (ASCO). Check out the stories below for write-ups of the most important information to come out of this year's event.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
2 experts in this video
Related Content
The belantamab mafodotin regimens earned approval in Japan from the Ministry of Health, Labour and Welfare in May 2025 based on findings from the DREAMM-7 and DREAMM-8 trials.

CHMP Recommends Approval of Belantamab Mafodotin Combos in Multiple Myeloma

Russ Conroy
May 23rd 2025
Article

The European Commission is expected to approve the belantamab mafodotin combinations for this multiple myeloma population in the third quarter of 2025.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

Tim Cortese
May 23rd 2025
Article

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

The positive CHMP opinion is based on results from the phase 1b/2 FELIX trial evaluating obe-cel in relapsed/refractory B-cell ALL.

Obe-Cel Receives Positive CHMP Opinion for R/R B-Cell ALL

Roman Fabbricatore
May 23rd 2025
Article

The positive CHMP opinion is based on results from the phase 1b/2 FELIX trial evaluating obe-cel in relapsed/refractory B-cell ALL.

Data from the INCITE-ES study show 100% technical success with pulsed electric field energy delivery before surgical resection.

Pulsed Electric Field Ablation May Show Feasibility, Safety in Early NSCLC

Russ Conroy
May 23rd 2025
Article

Data from the INCITE-ES study show 100% technical success with pulsed electric field energy delivery before surgical resection.